Clinical trial
Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer
NCT00415818 · Transgene, Industry · Completed
Key facts
| NCT number | NCT00415818 |
|---|---|
| Title | Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer |
| Official title | A Phase IIb Multicentric Controlled Study Evaluating the Therapeutic Vaccine TG4010(MVA-MUC1-IL2) as an Adjunct to Standard Chemotherapy in Advanced Non Small Cell Lung Cancer |
| Lead sponsor | Transgene, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Biological, Drug |
| Interventions | MVA-MUC1-IL2, 1st line Chemotherapy |
| Enrollment | 148 |
| Start date | Dec 1, 2005 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Dec 25, 2006 |
| Last update posted | Jul 16, 2014 |
| Countries | France, Germany, Hungary, Poland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: